Prosecution Insights
Last updated: November 20, 2026
Application No. 18/724,765

COLLAGEN CROSS-LINKER AND USES THEREOF

Non-Final OA §112
Filed
Jun 27, 2024
Priority
Feb 04, 2022 — provisional 63/306,748 +2 more
Examiner
WELLS, LAUREN QUINLAN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Curators of the University of Missouri
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
129 granted / 261 resolved
-10.6% vs TC avg
Strong +60% interview lift
Without
With
+59.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
89 currently pending
Career history
354
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
36.0%
-4.0% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 261 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is responsive to the Response to Election/Restriction and Amendment filed 09/28/2026, which amended claims 1 and 9, and added claim 10. Claims 1-10 are pending. Priority This application claims the following priority: PNG media_image1.png 95 669 media_image1.png Greyscale Election/Restrictions Note: Applicant’s amendment to independent claim 1 modifies the technical feature of the instant claims. Applicant's election with traverse of Group I in the reply filed on 09/28/2026 is acknowledged. The traversal is on the ground(s) that Claims 1 and 9 as amended claim mixtures comprising each of TRI-1, TRI-2 and TRI-3, which constitutes the special technical feature. This argument is found persuasive. The Restriction Requirement of 04/28/2026, is hereby withdrawn. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claims 1-10 are pending and examined on the merits herein. Claim Objections Claims 1, 4, 9, and 10 are objected to because of the following informalities: -In claim 1, the term “further” in the phrase “further wherein R16-R18” on pg. 2 of the claim set, should be deleted. -In claim 1, the term “further” in the phrase “further wherein R12-R13” on pg. 3 of the claim set, should be deleted. -In claim 1, the term “further” in the phrase “further wherein R13-R14” on pg. 4 of the claim set, should be deleted. -In claim 4, the term “further” in the phrase “further wherein R16-R18” on pg. 5 of the claim set, should be deleted. -In claim 4, the term “further” in the phrase “further wherein R12-R13” on pg. 6 of the claim set, should be deleted. -In claim 4, the term “further” in the phrase “further wherein R13-R14” on pg. 7 of the claim set, should be deleted. -In claim 9, the term “further” in the phrase “further wherein R16-R18” on pg. 8 of the claim set, should be deleted. -In claim 9, the term “further” in the phrase “further wherein R12-R13” on pg. 9 of the claim set, should be deleted. -In claim 9, the term “further” in the phrase “further wherein R13-R14” on pg. 10 of the claim set, should be deleted. -In claim 10, the term “further” in the phrase “further wherein R16-R18” on pg. 11 of the claim set, should be deleted. -In claim 10, the term “further” in the phrase “further wherein R12-R13” on pg. 12 of the claim set, should be deleted. -In claim 10, the term “further” in the phrase “further wherein R13-R14” on pg. 12 of the claim set, should be deleted. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. -In claims 1, 4 and 9-10, the Markush groups recited for R1-R15 and R1-R11 and R1-R12, in reference to TRI-1, TRI-2, and TRI-3, respectively, render the claims indefinite. It is not clear if the recited members of the Markush group are the recited chemical group or if it is any chemical group that comprises a halide, a hydroxide, an amine, a linear alkyl, a branched alkyl, a cyclic alkyl, a heteroalkyl, an alkenyl, or an alkynyl. For example, it is not clear if a) “hydroxides,” is referencing a “-OH” group at any one of R1-R15 and R1-R11 and R1-R12, or if it means that any one of R1-R15 and R1-R11 and R1-R12 can be any chemical group that comprises a hydroxide, such as phenol, or b) “halides” is referencing a single halogen at any one of R1-R15 and R1-R11 and R1-R12, or if it means that any one of R1-R15 and R1-R11 and R1-R12 can be any chemical group that comprises a halogen. This rejection can be overcome by removing the plural form of the Markush members so that each Markush group recites “hydrogen, halide, hydroxide, amine, linear alkyl, branched alkyl, cyclic alkyl, heteroalkyl, alkenyl, and alkynyl.” -TRI-2 and TRI-3, as depicted in claims 1, 4, 9, and 10, are the same compound when R6 of TRI-3 is H. As such, it is not clear if the collagen crosslinker mixture must comprise distinct compounds of TRI-2 and TRI-3 or if a collagen crosslinker mixture comprising TRI-1 and TRI-3 wherein R6 is H, meets the limitation of a collagen crosslinker mixture comprising TRI-1, TRI-2, and TRI-3. -Claim 10 recites “A method of inhibiting matrix metalloproteinase (MMP) activity, the method comprising applying a TRI mixture, the TRI mixture comprising,” which renders the claim indefinite. It is not clear where or to what the TRI mixture is applied. It is not clear if applying comprises a step of administering or contacting, or if the applying merely means combining TRI-1, TRI-2, and TRI-3 as a mixture in whatever structure is utilized to house the mixture. All other claims not specifically recited are rejected for depending from an indefinite claim and failing to cure the deficiency. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 2 depends from claim 1 and states that “every ‘-R’ substituent on TRI-1, TRI-2, and TRI-3 is hydrogen.” However, none of R16-R18 and R12-R13 and R13-R14 in reference to TRI-1, TRI-2, and TRI-3, respectively, as defined in claim 1, can be H. As such, claim 2 broadens the scope of claim 1 from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 112(a)-Written Description & Scope of Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 9 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See MPEP 2163. Instant independent claim 9 is directed toward a dentin treatment mixture comprising a dental adhesive and a collagen crosslinker mixture comprising: PNG media_image2.png 489 535 media_image2.png Greyscale PNG media_image3.png 533 541 media_image3.png Greyscale PNG media_image4.png 440 636 media_image4.png Greyscale . The specification does not further define the members of the Markush group. Thus, in view of the broadest reasonable interpretation (MPEP 2173.02), the members of the Markush group are interpreted as both substituted and unsubstituted groups, wherein the substituted groups encompass any substitution, such as a polymer, a nucleic acid, or a metal complex. As discussed in MPEP 2163 II.A(3)(a)(ii), the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice (see i)(A)above), reduction to drawing (see i)(B) above), or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the inventor was in possession of the claimed genus. . .A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The instant specification only provides a single example of a single species of each of TRI-1, TRI-2, TRI-3: PNG media_image5.png 349 575 media_image5.png Greyscale , as a collagen crosslinker mixture in a dentin treatment mixture: These species are limited to a compounds wherein R1-R15 of TRI-1, R1-R11 of TRI-2, and R1-R5, R7-R12 of TRI-3 are H, and R6 of TRI-3 is CH2CH3, and wherein R16-R17 of TRI-1, R12-R13 of TRI-2, and R13-R14 of TRI-3 are CH2. As such, the species disclosed in the specification are very limited in scope when compared to the expansive scope of the compounds of TRI-1, TRI-2, and TRI-3. There is a vast scope in the claims that has no representation at all or homology to the disclosed species in relation to their use as a collagen crosslinker mixture in a dentin treatment. The disclosure does not adequately reflect the structural diversity of the claimed genus in reference to its use as a collagen crosslinker mixture in a dentin treatment, that is representative of the full variety or scope of the genus. In addition, there is no establishment of a reasonable structure-function correlation in the disclosure or prior art that clearly imparts the activity of the TRI-1, TRI-2, and TRI-3 mixture as a collagen crosslinker mixture in a dentin treatment. While US 8,940,684 (IDS of 06/27/2024) teaches a compound of instant TRI-1, wherein R1-R15 are H and R16-R18 are CH2, this compound is taught as an antifungal agent (title, abstract, Col. 4, line 30-Col. 5, line 35). While US 2017/0202751 (IDS of 06/27/2024) teaches a dental etchant composition comprising one or more dentin collagen cross-linking agents comprising one or more polyphenols, such as proanthocyanidins (title, abstract; pg. 6, claims 1-3), it does not teach any one of the instantly claimed compounds in the instant collagen crosslinker mixture. In view of the teachings of the instant disclosure and that of the prior art, it is not possible to determine a core structure of the TRI-1, TRI-2, and TRI-3 mixture that is critical to impart its activity as a collagen crosslinker in a dentin treatment. Claim 10 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of inhibiting matrix metalloproteinase (MMP) activity by administering a composition comprising PNG media_image5.png 349 575 media_image5.png Greyscale to dentin, does not reasonably provide enablement for a method of inhibiting MMP activity comprising applying a composition comprising TRI-1, TRI-2, and TRI-3 as defined in instant claim 10. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The criteria for enablement set out in the In re Wands, MPEP 2164.01(a), considers the following factors: Breadth of the Claims Instant independent claim 10 is directed toward a method of inhibiting MMP activity by applying a mixture comprising: PNG media_image2.png 489 535 media_image2.png Greyscale PNG media_image3.png 533 541 media_image3.png Greyscale PNG media_image4.png 440 636 media_image4.png Greyscale . The specification does not further define the members of the Markush group. Thus, in view of the broadest reasonable interpretation, the members of the Markush group are interpreted as both substituted and unsubstituted groups, wherein the substituted groups encompass any substitution, such as a polymer, a nucleic acid, or a metal complex. Thus, the breadth of the claims is great. Level of Skill in Art The level of skill in the art is a clinician or a scientist with a PhD. State of the Prior Art The prior art is silent regarding a mixture of the instantly claimed compounds. While US 8,940,684 (IDS of 06/27/2024) teaches a compound of instant TRI-1, wherein R1-R15 are H and R16-R18 are CH2, this compound is taught as an antifungal agent (title, abstract, Col. 4, line 30-Col. 5, line 35) and not for use in inhibiting MMP activity. While US 2017/0202751 (IDS of 06/27/2024) teaches a method of performing a dental restoration on a mammal’s tooth by contacting the tooth with a dental etchant composition comprising one or more dentin collagen cross-linking agents such as the polyphenol, proanthocyanidins (title, abstract; pg. 6, claims 1-3), it does not teach a method of inhibiting MMP activity by applying a TRI mixture and does not tach any one of the instantly claimed compounds in the instant TRI mixture. Predictability in the Art As seen by instant Figure 4B, known collagen crosslinkers have variable activity in inhibiting matrix metalloproteinase: PNG media_image6.png 300 522 media_image6.png Greyscale , wherein EGCG, QC, and GEN are polyphenols and have the following structures: PNG media_image7.png 462 734 media_image7.png Greyscale ; PNG media_image8.png 183 256 media_image8.png Greyscale , and PNG media_image9.png 247 258 media_image9.png Greyscale , respectively, and EDC/NHS is 3-dimethylaminopropyl carboxamide hydrochloride/N-hydroxy-succinimide. Thus, as can be seen by the table in Figure 4B and the structure of the tested compounds, the art of inhibiting MMP activity in dentin, with collagen crosslinkers known in the art, is unpredictable. Working Examples The instant specification only provides a single working example of a method of inhibiting MMP activity by administering a mixture of PNG media_image10.png 349 575 media_image10.png Greyscale to dentin (Example 3, beginning on pg. 23 of the instant specification). Direction and Guidance In view of the unpredictability of the art, the lack of working examples, and the prior art’s silence regarding a mixture comprising instant TRI-1, TRI-2, and TRI-3, as generically defined in instant claim 10, the instant disclosure lacks sufficient direction and guidance to use the instantly claimed TRI mixture in a method of inhibiting MMP activity. Quantity of Experimentation The amount of experimentation required to determine which groups, including substituted groups, in each variable group of each of TRI-1, TRI-2, and TRI-3, in which combinations of TRI-1, TRI-2, and TRI-3, are effective to inhibit MMP activity would be astronomical, amount to invention and not development; it is an undue amount of experimentation. Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Zhang (New tris(dopamine) derivative as an iron chelators. Synthesis, solution thermodynamic stability, and antioxidant research, published 2017, PTO-892) teaches a compound of instant TRI-1: PNG media_image11.png 219 216 media_image11.png Greyscale (pg. 30). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAUREN WELLS/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 27, 2024
Application Filed
Nov 02, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799116
CYCLIC FORMYL AND CYCLIC KETONE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE
5y 0m to grant Granted Nov 17, 2026
Patent 12797365
COMPOSITIONS AND METHODS FOR MODULATING TRP CHANNEL ACTIVITY
4y 0m to grant Granted Nov 17, 2026
Patent 12797400
NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES
4y 0m to grant Granted Nov 17, 2026
Patent 12788768
COMPOSITION COMPRISING CANNABINOIDS, AND/OR TERPENS, AND METHODS OF USING SAME
3y 8m to grant Granted Nov 10, 2026
Patent 12788737
SUBSTANCES FOR TREATMENT OF HYPERURICAEMIA
3y 6m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
99%
With Interview (+59.5%)
3y 0m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 261 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month